Reaction
Tumour Hyperprogression reporting signals
As of the last recalculation, Tumour Hyperprogression appears in 232 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 203.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 118 | 203.7 | 204.0 |
| Durvalumab | 36 | 187.7 | 188.1 |
| Atezolizumab | 30 | 79.5 | 79.5 |
| Pemetrexed Disodium | 14 | 35.0 | 35.0 |